N
Ngan B. Doan
Researcher at Ronald Reagan UCLA Medical Center
Publications - 3
Citations - 82
Ngan B. Doan is an academic researcher from Ronald Reagan UCLA Medical Center. The author has contributed to research in topics: Messenger RNA & Gene silencing. The author has an hindex of 3, co-authored 3 publications receiving 47 citations.
Papers
More filters
Journal ArticleDOI
RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling.
Xin-Yi Loh,Qiao-Yang Sun,Ling-Wen Ding,Anand Mayakonda,Nachiyappan Venkatachalam,Mei-Shi Yeo,Tiago C. Silva,Tiago C. Silva,Jin-Fen Xiao,Ngan B. Doan,Jonathan W. Said,Xue-Bin Ran,Siqin Zhou,Pushkar Dakle,Pavithra Shyamsunder,Angele Pei-Fern Koh,Ruby Yun-Ju Huang,Benjamin P. Berman,Benjamin P. Berman,Soo Yong Tan,Henry Yang,De-Chen Lin,H. Phillip Koeffler,H. Phillip Koeffler +23 more
TL;DR: Findings reveal an indispensable role of ZFP36L1 as a posttranscriptional safeguard against aberrant hypoxic signaling and abnormal cell cycle progression.
Journal ArticleDOI
SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells.
Qiao-Yang Sun,Ling-Wen Ding,Kara Johnson,Siqin Zhou,Jeffrey W. Tyner,Henry Yang,Ngan B. Doan,Jonathan W. Said,Jin Fen Xiao,Xin-Yi Loh,Xue Bin Ran,Nachiyappan Venkatachalam,Zhentang Lao,Ye Chen,Liang Xu,Li Fei Fan,Li Fei Fan,Wenwen Chien,De-Chen Lin,H. Phillip Koeffler,H. Phillip Koeffler +20 more
TL;DR: It is shown that SOX7 was significantly downregulated in different cancer types, especially in lung and breast cancers, and Panobinostat, an FDA approved pan-HDAC inhibitor, could elevate and restore SoX7 expression in SOX6 silenced lung cancer cells.
Journal ArticleDOI
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.
Deepika Kanojia,Manoj Garg,Jacqueline Martinez,M T Anand,Samuel B. Luty,Ngan B. Doan,Jonathan W. Said,Charles Forscher,Jeffrey W. Tyner,H. Phillip Koeffler,H. Phillip Koeffler +10 more
TL;DR: Two large-scale kinase screenings identified novel liposarcoma targets and a FDA-approved inhibitor, ponatinib with clear anti-liposARcoma activity highlighting its potential therapy for treatment of this deadly tumor.